Vimarsana
Biggest News Aggregation in the World

Vivek Narayan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vivek Narayan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vivek Narayan Today - Breaking & Trending Today

American College of Cardiology (ACC) Program Set for Cardiac Oncology Conference, "Advancing the Cardiovascular Care of the Oncology Patient" - Vimarsana News

American College of Cardiology (ACC) Program Set for Cardiac Oncology Conference, "Advancing the Cardiovascular Care of the Oncology Patient"

The American College of Cardiology’s Cardiac Oncology Conference, “Advancing the Cardiovascular Care of the Oncology Patient,” will be held at the Heart House in Washington, D.C., Feb. 9-11, 2024. The event is offered as an interdisciplinary and interspecialty course with a robust program providing clinicians and researchers with the tools needed to improve the cardiovascular (CV) health of cancer patients in everyday practice.

Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma - Vimarsana News

Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

A Look at Novel Immune Therapies for Kidney Cancer - Vimarsana News

A Look at Novel Immune Therapies for Kidney Cancer

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC - Vimarsana News

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023 - Vimarsana News

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

First presentation of results from CheckMate -901 show survival benefit with Opdivo + chemotherapy in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma who...